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Thesis overview 
Multiple Sclerosis (MS) is an autoimmune disease involving demyelination and 
neurodegeneration of the central nervous system (Compston & Coles, 2002).  In the UK it is 
the most common form of non-traumatic neurological disability in young adults (Compston 
& Coles, 2008).  Common symptoms of MS include sensory disturbance in limbs, visual 
loss, fatigue, mood disturbance and motor disturbance (Bobholz & Gremely, 2011).  MS is 
often categorised depending on symptoms.  The most common type is relapsing remitting, 
experienced by approximately 80% of people at onset (NICE, 2014).  It is characterised by 
relapses, where new or existing symptoms become more severe, and remissions, a partial or 
total recovery of symptoms.  Other types of MS include secondary progressive (gradual 
progression of symptoms and only partial recovery during remissions) and primary 
progressive (no periods of remission and gradual progression of symptoms).   There is 
currently no cure for MS, current treatments include medications aimed at modifying disease 
activity and symptom management. 
Approximately 50% of people with MS experience cognitive symptoms (NICE, 
2014).  Cognitive difficulties in people with MS have been shown to effect social 
functioning and quality of life (Rao et al., 1991).  Clinicians often rely on MS patients’ 
subjective reports of their difficulties in cognitive functioning.  However, studies have 
shown that the relationship between MS patients’ self-reported cognitive difficulties and 
their objective cognitive functioning, as measured by neuropsychological tests, is 
inconsistent.  Several studies have demonstrated a discrepancy between self-reported 
cognitive functioning and objective performance on neuropsychological tests (Carone, 
Benedict, Munschauer, Fishman, & Weinstock-Guttman, 2005; Julian, Merluzzi, & Mohr, 
2007; Lovera et al., 2006; Middleton, Denney, Parmenter, & Lynch, 2006).  Both fatigue 
(Kinsinger, Lattie, & Mohr, 2010) and depression (Kinsinger et al., 2010; Maor, Olmer, & 
Mozes, 2001) have been shown to influence MS patients’ self-reported cognitive 
functioning, more than their objective functioning.  MS patients with higher levels of 
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depression and fatigue report more subjective cognitive difficulties.  Chapter 1 of this thesis 
systematically reviews the literature examining the relationship between subjective and 
objective cognitive functioning, and examines whether depression and fatigue influence MS 
patients ability to accurately perceive their cognitive functioning. 
The systematic review demonstrated inconsistent findings when examining the 
relationship between subjective and objective cognitive functioning.  Both fatigue and 
depression were found to be associated with subjective cognitive functioning, explaining 
some of the variance.  However, other variables are likely to influence this relationship and 
these influential variables are investigated in Chapter 2. 
Self-efficacy has previously been shown to play an important role in the MS 
population.  It can be described as a level of self-confidence about an individual’s ability to 
manage specific situations or conditions, relating to perceptions of competency, rather than 
actual performance (Ng et al., 2013).  A recent study by Schmitt, Goverover, DeLuca, and 
Chiaravalloti (2014) demonstrated that self-efficacy influences MS patients subjective 
cognitive functioning, after controlling for both depression and functional impairment.  
Chapter 2 builds upon the findings of the review paper and additionally examines the role of 
self-efficacy as a predictor of subjective cognitive functioning and quality of life.   
The empirical paper has demonstrated that self-efficacy is a significant predictor of 
subjective cognitive functioning and quality of life even after controlling for age, MS 
duration, depression, anxiety, fatigue and objective cognitive functioning.  People with MS 
reporting higher levels of self-efficacy reported fewer cognitive difficulties and greater 
quality of life.  As self-efficacy was shown to be a significant predictor of subjective 
cognitive functioning and quality of life, even after controlling for other influential variables, 
it seems prudent for future research to target self-efficacy for intervention.  Interventions 
aimed at improving self-efficacy in people with MS could potentially improve their accuracy 
at appraising their cognitive functioning and improve their quality of life. 
 
3 
 
References 
Bobholz, J., & Gremely, S. (2011). The little black book of neuropsychology: a syndrome-
based approach In M. Schoenberg & J. Scott (Eds.), Online access with purchase: 
Springer: New York ; Springer. 
Carone, D. A., Benedict, R. H. B., Munschauer, F. E., III, Fishman, I., & Weinstock-
Guttman, B. (2005). Interpreting patient/informant discrepancies of reported 
cognitive symptoms in MS. Journal of the International Neuropsychological 
Society, 11(5), 574-583. doi: 10.1017/S135561770505068X 
Compston, A., & Coles, A. (2002). Seminar: Multiple sclerosis. The Lancet, 359, 1221-1231. 
doi: 10.1016/S0140-6736(02)08220-X 
Compston, A., & Coles, A. (2008). Seminar: Multiple sclerosis. The Lancet, 372, 1502-1517. 
doi: 10.1016/S0140-6736(08)61620-7 
Julian, L., Merluzzi, N. M., & Mohr, D. C. (2007). The relationship among depression, 
subjective cognitive impairment, and neuropsychological performance in multiple 
sclerosis. Multiple Sclerosis, 13(1), 81-86.  
Kinsinger, S. W., Lattie, E., & Mohr, D. C. (2010). Relationship between depression, 
fatigue, subjective cognitive impairment, and objective neuropsychological 
functioning in patients with multiple sclerosis. Neuropsychology, 24(5), 573-580.  
Lovera, J., Bagert, B., Smoot, K. H., Wild, K., Frank, R., Bogardus, K., . . . Bourdette, D. N. 
(2006). Correlations of Perceived Deficits Questionnaire of multiple sclerosis quality 
of life inventory with Beck Depression Inventory and neuropsychological tests. 
Journal of Rehabilitation Research and Development, 43(1), 73-82.  
4 
 
Maor, Y., Olmer, L., & Mozes, B. (2001). The relation between objective and subjective 
impairment in cognitive function among multiple sclerosis patients - The role of 
depression. Multiple Sclerosis, 7(2), 131-135.  
Middleton, L. S., Denney, D. R., Parmenter, B., & Lynch, S. G. (2006). The relationship 
between perceived and objective cognitive functioning in multiple sclerosis. 
Archives of Clinical Neuropsychology, 21(5), 487-494. doi: 
10.1016/j.acn.2006.06.008 
Ng, A., Kennedy, B., Hutchinson, B., Ingram, A., Vondrell, S., Goodman, T., & Miller, D. 
(2013). Self-efficacy and health status improve after a wellness program in persons 
with multiple sclerosis. Disability and Rehabilitation, 32(12), 1039-1044.  
NICE. (2014). Multiple Sclerosis:  Management of multiple sclerosis in primary and 
secondary care. London: NICE. 
Rao, S., Leo, G., Ellington, L., Nauertz, T., Bernardin, L., & Unverzagt, F. (1991). Cognitive 
dysfunction in multiple sclerosis. II. Impact on employment and social functioning. 
Neurology, 41(5), 692-696.  
Schmitt, M., Goverover, Y., DeLuca, J., & Chiaravalloti, N. (2014). Self-efficacy as a 
predictor of self-reported physical, cognitive, and social functioning in multiple 
sclerosis. Rehabilitation Psychology, 59(1), 27-34. doi: 10.1037/a0035288 
 
5 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: The association of depression and fatigue with the accuracy 
of subjective reports of cognitive functioning in Multiple Sclerosis: A 
systematic review
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Abstract 
Health clinicians often rely on MS patients’ self-reports of their cognitive functioning to 
inform treatment planning.  However, a number of studies have found discrepancies between 
MS patients’ reports of subjective cognitive functioning and their objective cognitive 
functioning, as measured by neuropsychological tests.  This discrepancy is of particular 
interest to researchers and clinicians when people with MS report cognitive difficulties that 
are not present on objective cognitive testing.  It has been reported that fatigue and 
depression may be associated with this discrepancy.   This systematic review aims to 
examine the extent to which fatigue and depression are associated with MS patients’ self-
reported cognitive functioning. Four electronic databases were systematically searched, 
identifying 37 articles, of which seven met the inclusion criteria for the review.  Of the 
studies reviewed, a weak relationship was observed between subjective and objective 
cognitive functioning. Fatigue, and to a lesser extent depression, were found to be positively 
associated with MS patients’ subjective reports difficulties with their cognitive functioning.  
The findings are discussed in relation to clinical implications for assessment and treatment, 
and also in terms of recommendations for future research. 
Keywords 
Depression, fatigue, Multiple Sclerosis, objective cognitive functioning, subjective cognitive 
functioning  
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Introduction 
 
Multiple Sclerosis (MS) is an autoimmune disease involving demyelination and 
neurodegeneration of the central nervous system (Compston & Coles, 2002).  The most 
common symptoms of MS include sensory disturbance in limbs, visual loss, fatigue, mood 
disturbance and motor disturbance (Bobholz & Gremely, 2011).  Decline in cognitive 
function is also common affecting approximately 50% of MS patients (Grazioli, Yeh, 
Benedict, Parrish, & Weinstock-Guttman, 2008).  The cognitive functions most commonly 
affected are information processing speed, complex attention, learning and memory, 
perceptual skills, word finding and executive functioning (Bobholz & Gremely, 2011).  
Research has shown that cognitive dysfunction in MS patients has a significant impact on 
daily living, lifestyle, social functioning, overall quality of life (Rao et al., 1991), medication 
adherence (Bruce, Hancock, & Lynch, 2010) and employment status (Moore et al., 2013). 
Health clinicians often rely on MS patients’ self-reports of their cognitive 
functioning in order to inform their treatment planning and evaluation.  A small proportion 
of studies have found participants are accurate at reporting their cognitive functioning, when 
compared to their objective cognitive functioning, as measured by neuropsychological tests.  
These studies have found MS participants who perform poorly on neuropsychological tests 
report greater cognitive difficulties (Chiaravalloti & DeLuca, 2003; van der Hiele, 
Spliethoff-Kamminga, Ruimschotel, Middelkoop, & Visser, 2012).  However, the majority 
of the studies in this area have noted only weak associations, or no associations, between MS 
patients’ self-reported cognitive functioning and objective assessments of their cognitive 
functioning (Benedict et al., 2004; Carone, Benedict, Munschauer, Fishman, & Weinstock-
Guttman, 2005; Christodoulou et al., 2005; Deloire et al., 2006; Demers et al., 2011; Gold, 
Schulz, Mönch, Schulz, & Heesen, 2003; Julian, Merluzzi, & Mohr, 2007; Kinsinger, Lattie, 
& Mohr, 2010; Lovera et al., 2006; Maor, Olmer, & Mozes, 2001; Middleton, Denney, 
Parmenter, & Lynch, 2006).  These studies have demonstrated either no systematic 
relationship, or demonstrated that sometimes MS patients might over-report cognitive 
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difficulties when none are apparent on objective neuropsychological tests, or conversely, 
under-report cognitive difficulties that are apparent on objective tests.  Researchers and 
clinicians are particularly interested when people with MS report cognitive difficulties when 
none are objectively present, as this can be incorrectly attributed to MS related neurological 
change, possibly leading to unnecessary treatment.  Clinicians need to be able to formulate 
whether self-reported cognitive difficulties are due to MS related change or other factors, to 
inform the most appropriate intervention.   The focus of the research has been to explore the 
factors that might be associated with these discrepant presentations.  Factors that appear to 
have some association with discrepancies in cognitive functioning include levels of fatigue 
(Bol, Duits, Hupperts, Verlinden, & Verhey, 2010; Deloire et al., 2006; Kinsinger et al., 
2010; Marrie, Chelune, Miller, & Cohen, 2005; Middleton et al., 2006; Roberg, Bruce, 
Lovelace, & Lynch, 2012) and depression (Benedict et al., 2004; Bruce & Arnett, 2004; 
Christodoulou et al., 2005; Deloire et al., 2006; Demers et al., 2011; Julian et al., 2007; 
Kinsinger et al., 2010; Lovera et al., 2006; Maor et al., 2001; Middleton et al., 2006; van der 
Hiele et al., 2012).  However, the findings have been variable.  
Depression and subjective reports of cognitive functioning  
Depression is experienced by approximately 50% of people with MS (Siegert & Abernethy, 
2005).  Several studies report that MS patient’s perceptions of their cognitive functioning are 
influenced more by depression than objective functioning. For example, Maor et al. (2001) 
objectively assessed a number of cognitive domains and found depression influenced 
subjective reports of cognitive functioning more than objective assessments of cognitive 
functioning.  These findings have been corroborated by a number of studies (Benedict et al., 
2004; Bruce & Arnett, 2004; Christodoulou et al., 2005; Deloire et al., 2006; Demers et al., 
2011; Julian et al., 2007; Kinsinger et al., 2010; Lovera et al., 2006; Maor et al., 2001; 
Middleton et al., 2006; van der Hiele et al., 2012).  The majority of these studies demonstrate 
that the more depressed the person is, the more they overestimate cognitive functioning 
difficulties.  
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Conversely, Smith and Arnett (2010) did not find depression to be related to 
subjective cognitive impairment.  They found that MS participants who overestimated their 
executive functioning difficulties were no more depressed than those who were more 
accurate at reporting their cognitive functioning.  In addition, Gold et al. (2003) found a 
discrepancy between MS patients’ self-reported cognitive functioning and their objective 
functioning.  However, this discrepancy didn’t appear to be related to levels of depression.  
A review of the literature has concluded that there is no consistent relationship 
between depression and objective cognitive functioning in MS patients (Brassington & 
Marsh, 1998).   
Fatigue and subjective reports of cognitive functioning  
Fatigue, which is reported to affect up to 92% of people with MS (Brañas, Jordan, Fry-
Smith, Burls, & Hyde, 2000), is also observed to be associated with perceptions of cognitive 
functioning.  Bol et al. (2010) found that fatigue, along with anxiety and depression, 
significantly contributed to discrepancies in subjective cognitive functioning.  In addition, 
several authors have corroborated these findings, demonstrating fatigue to influence MS 
patient’s accuracy at reporting their cognitive functioning.  As self-reported fatigue 
increases, so do MS patients’ subjective cognitive complaints (Deloire et al., 2006; Kinsinger 
et al., 2010; Marrie et al., 2005; Middleton et al., 2006; Roberg et al., 2012).   Middleton et 
al. (2006) found fatigue, along with disability, anxiety and depression were unique predictors 
of subjective cognitive functioning, even when the variance accounted for by objective 
cognitive performance was removed. 
The majority of studies report that there is no association between fatigue and 
objective cognitive functioning (Bol et al., 2010; Fraser & Stark, 2003; Paul, Beatty, 
Schneider, Blanca, & Hames, 1998).  Although MS patients often perceive fatigue to affect 
their cognitive ability, their neuropsychological test performance does not appear to be 
associated with their levels of fatigue (Parmenter, Denney, & Lynch, 2003).   
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It is the case that discrepancies sometimes occur between subjective and objective 
cognitive functioning.  Both depression and fatigue appear to be associated with subjective 
reports of cognitive functioning.  However, neither seems to be consistently associated with 
objective reports of cognitive functioning in MS patients.  Clarifying and understanding 
these relationships will be important to the formulation and treatment planning for MS 
patients.  For example, if a person with MS reports cognitive difficulties, it might be 
assumed that the most helpful intervention would be medical treatment for a relapse or 
compensatory cognitive strategies.  However, if they are reporting memory difficulties that 
are not observed on objective neuropsychological tests, cognitive strategies alone are 
unlikely to be useful.  In this case, the most appropriate intervention might be a therapeutic 
psychological intervention.  In order to usefully formulate MS patients’ appraisals of their 
cognitive functioning it is necessary to determine whether depression and fatigue influence 
their subjective cognitive functioning.  To date, there has not been a systematic review of 
these studies specifically looking at the relationship of fatigue and depression with subjective 
reports of cognitive functioning.   Therefore, the aim of this review is to systematically 
analyse the current literature, investigating the accuracy of individuals with MS at reporting 
their cognitive functioning when compared to their objective cognitive functioning on 
neuropsychological tests.  In addition, depression and fatigue will be examined to determine 
whether these factors influence participants’ subjective reporting of their cognitive 
functioning.  Given the high prevalence of depression and fatigue in MS, and that research 
suggests both can influence MS patient’s ability to accurately perceive their cognitive 
functioning, the focus of this review will be to examine the individual and combinatorial 
effects.   
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Method 
 
Inclusion criteria  
Studies were included that met the following criteria: (a) patients had a diagnosis of MS (b) 
included a measure of subjective cognitive impairment (c) included a measure of objective 
cognitive impairment (d) included both a measure of depression and fatigue (e) available in 
English language.  All studies that did not meet these criteria were excluded. 
 
Search strategy 
The initial strategy involved the search of four major electronic databases (MEDLINE, 
Scopus, Psych Info and Web of Knowledge).   To limit the search to the desired studies, key 
words anywhere in the title for the terms ‘MS’, ‘cogniti* impairment’, ‘fatigue’ and 
‘depression’ were used and returned a total of 1109 studies.  After removing duplicates, 696 
studies titles and abstracts were screened for content relevance by applying the inclusion and 
exclusion criteria.  Where the title and abstract did not clearly indicate the degree of 
relevance to the topic, the article itself was reviewed.  This was applicable for 37 articles.  
Thirty two articles did not meet the inclusion criteria and were excluded from the study.  The 
search strategy yielded five relevant studies to be included in the review.  A further hand 
search of relevant journals bibliographies, and thesis projects, were also conducted to 
discover additional references not identified in the primary search.  This yielded one 
additional study.  These six studies were initially reviewed and rated for quality.  Data for 
review were gathered from the full text copies of the studies (figure 1). 
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Figure 1. Flow chart demonstrating the process used to select publications for review. 
  
Titles and abstracts identified and 
screened (N = 1109) 
Duplicates removed (N = 413) 
Potentially relevant publications 
screened for suitability (N = 696) 
Full texts assessed for eligibility 
(N =37).  Five publications 
identified 
Hand search identified one 
further publication  
Six publications identified for 
review  
Inclusion Criteria: 
1. Multiple Sclerosis AND 
2. Cogniti* impairment AND 
3. Depression AND 
4. Fatigue  
Exclusion Criteria: 
Drugs trials of cognition  
Not relating to cognition  
Neuroimaging studies of 
cognition  
Relating only to quality of life 
and physical disability only   
Exclusion Criteria: 
No subjective measure of 
cognitive functioning and 
objective measure of cognitive 
functioning 
No depression measure  
No fatigue measure  
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Quality appraisal 
The 16 item Quality Assessment Tool (QATSDD, Sirriyeh, Lawton, Gardner, & Armitage, 
2012) was used to assess the quality of the studies (appendix B).  The QATSDD, is designed 
to assess quality of methodologically diverse research.  The papers included in this review 
were of varied methodology and the QATSDD provided a standardised approach to 
reviewing the literature. The QATSDD has demonstrated good reliability and validity 
(Sirriyeh et al., 2012).  Each of the 16 items were then totalled to create an overall score, 
which was used as a guide when interpreting the quality of the studies.  The first author rated 
each of the studies and discussed the quality with the other co-authors.  The limitations of 
each study are noted in appendix B. 
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Results 
Design and aims 
Six papers met the inclusion criteria and were included in the review (appendix B).  
However, Roberg et al’s. (2012) study reported two individual studies.  Therefore, for the 
purpose of this review they were considered individually and referred to as study one and 
study two, making a total of seven individual studies.  Of the seven studies, five papers were 
cross-sectional and two were longitudinal in design.  Four studies included a control group 
(Deloire et al., 2006; Middleton et al., 2006; Roberg et al., 2012, study 1 & 2).   
The aims of each of the studies varied.  Three studies (Deloire et al., 2006; Marrie et 
al., 2005; Middleton et al., 2006) stated that their aim was to evaluate the relationship 
between subjective and objective cognitive impairment, as measured by neuropsychological 
tests, and identify variables that contribute to this relationship.  Roberg et al. (2012), study 
one and two, focused on one cognitive domain, speed of processing, investigating the 
relationship between self-reported processing speed and objective processing speed, 
examining the role of fatigue and emotion.  Study 1 examined this in a community sample 
and study 2 in a clinic sample.  Jones’ (2012) aim was to compare subjective and objective 
cognitive functioning, whilst considering the role of depression.  Kinsinger et al. (2010) 
aimed to examine the relationship between depression, fatigue, perceived cognitive 
functioning and objective neuropsychological performance, in the context of a clinical trial 
designed to treat depression with psychological interventions.  
Participants  
Across all seven studies, there were 952 participants in total, 837 MS patients and 115 
controls.  Experimental sample sizes ranged from 40 (Roberg et al., 2012, study 1) to 221 
(Middleton et al., 2006).  All control groups were much smaller than experimental groups.  
Of the four studies that used controls, one matched controls for age, gender and years of 
education (Deloire et al., 2006).  The majority of studies recruited from MS clinics (appendix 
B) The mean age of participants in the studies ranged from  37.17 (Deloire et al., 2006) to 
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51.60 (Jones, 2012).  Of the six studies that reported gender, there were higher numbers of 
female participants, possibly reflecting the higher prevalence of MS in woman than men 
(NICE, 2014).  Six studies reported disease duration, which ranged from 2.10 years (Deloire 
et al., 2006) to 18.33 years (Jones, 2012).  The disease duration in the Deloire et al. (2006) 
study was much shorter than the other studies as their inclusion criteria was newly diagnosed 
MS patients.    
Education 
All studies reported education levels of participants, with three studies reporting the mean, 
two studies categorising years of education into two groups (Deloire et al., 2006; Marrie et 
al., 2005), one categorising years of education into three groups (Roberg et al., 2012, study 
1) and one categorising years of education into four groups (Jones, 2012).  Of the studies 
reporting the mean years of education, they were quite similar, ranging from 14.80 years 
(Roberg et al., 2012, study 2) to 15.36 years (Kinsinger et al., 2010). 
Functional impairment  
Functional impairment, referring to patient’s physical ability, was measured in all studies.  
Four studies used the Expanded Disability Status Scale (EDSS, Kurtzke, 1983) (Deloire et 
al., 2006; Jones, 2012; Middleton et al., 2006; Roberg et al., 2012, study 2), two used the 
Multiple Sclerosis Functional Composite (MSFC, Fischer, Jak, Kniker, Rudick, & Cutter, 
2001) (Marrie et al., 2005; Roberg et al., 2012, study 1) and one used Guys Neurological 
Disability Scale (GNDS, Sharrack & Hughes, 1999) (Kinsinger et al., 2010).  Of the studies 
reporting the mean EDSS, the mean ranged from 2.0 (Deloire et al., 2006), signifying mild 
disability to 5.18 (Jones, 2012), indicating moderate to severe disability.  
Type of MS 
All studies reported MS subtype.  The majority of the participants had relapsing-remitting 
MS.  One study included only newly diagnosed participants with relapsing-remitting MS 
(Deloire et al., 2006) whereas the other six studies included relapsing-remitting, secondary 
16 
 
progressive and primary progressive, representing the most common types in the general MS 
population (NICE, 2014). 
Depression 
A variety of screening measures were used to measure depression, both Roberg et al. (2012), 
study two, and Jones (2012) used the Beck Depression Inventory – Fast Screen (BDI-FS, 
Beck, Steer, & Brown, 2000).  This questionnaire has been validated for use in the MS 
population.  Kinsinger et al. (2010) used a telephone version of the Hamilton Rating Scale 
for Depression (Hamilton, 1960), The Mongomery and Asberg Depression Rating Scale 
(MADRS, Montgomery & Åsberg, 1979) was used by Deloire et al. (2006), the Mental 
Health Inventory (Veit & Ware, 1983) was used in the Marrie et al. (2005) study, the 
Chicago Multiscale Depression Inventory (CMDI, Nyenhuis et al., 1998) was used in  
Roberg et al. (2012), study one, and the Centre for Epidemiological Studies-Depression 
Scale (CES-D, Radloff, 1977) by Middleton et al. (2006).   
Four studies commented on levels of depression.  Jones (2012) found 43% of MS 
patients in their study met the criteria for clinically significant levels of depression.   Of the 
studies employing a control group, there were differing findings, Roberg et al. (2012), study 
two found there were no significant differences in depression between controls and MS 
patients.  However, Roberg et al. (2012), study one, using a community sample, found 
significantly higher levels of depression in MS patients than controls, reporting a large effect 
size.  This was corroborated by Middleton et al. (2006), who found higher levels of reported 
depression in MS patients than controls matched for age, gender and education level. 
Fatigue  
The most common measure of fatigue was the Modified Fatigue Impact Scale (MFIS, Fisk, 
Pontefract, Ritvo, Archibald, & Murray, 1994) which is frequently used in MS research 
(Kinsinger et al., 2010; Marrie et al., 2005; Roberg et al., 2012, study 1 & 2).  Two studies 
(Jones, 2012; Middleton et al., 2006) used the Fatigue Severity Scale (FSS, Jones, 2012; 
Krupp, LaRocca, Muir-Nash, & Steinberg, 1989; Middleton et al., 2006) which is also 
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widely used in MS research and one study (Deloire et al., 2006) used the five graded fatigue 
subscale of the UK Neurological Disability Scale (Sharrack & Hughes, 1999).  Middleton et 
al. (2006) and Roberg et al. (2012), studies one and two, compared MS patients with controls 
and found higher levels of fatigue in MS patients.  A large effect size was reported in both 
Roberg studies. 
Subjective measures  
Five of the seven studies use self-report questionnaire measures to assess perceived cognitive 
functioning in multiple cognitive domains.  The most common questionnaire assessing 
multiple domains was the Perceived Deficits Questionnaire (PDQ, Sullivan, Edgley, & 
Dehoux, 1990) (Jones, 2012; Kinsinger et al., 2010; Marrie et al., 2005).  Two of the seven 
studies used a questionnaire which assessed only speed of processing, the Processing Speed 
Difficulties Scale (Roberg et al., 2012, studies 1 & 2).  Deloire et al. (2006) assessed 
cognitive complaints using only four questions from an adapted French version of the MS 
Quality of Life Questionnaire (Vernay, Gerbaud, & Clavelou, 2001). 
In addition, to self-report using the Cognitive Failures Questionnaire (CFQ, 
Broadbent, Cooper, FitzGerald, & Parkes, 1982), Middleton et al. (2006) also used a 
Performance Estimates interview, which consisted of questions assessing participants’ 
subjective performance, immediately following neuropsychological tests. 
Objective measures 
All studies employed face-to-face neuropsychological testing to assess objective cognitive 
functioning, with the exception of Kinsinger et al. (2010) who used telephone administered 
neuropsychological testing.  The most common cognitive domains to be assessed were speed 
of processing and memory.  All studies employed a measure of processing speed apart from 
Kinsinger et al. (2010), which could be due to the feasibility of employing a processing 
speed measure via telephone administration.  The majority of the studies assessed multiple 
cognitive domains, with the exception of Roberg et al. (2012), study two, who assessed only 
speed of processing and memory. 
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Two studies looked at objective cognitive functioning using composite scores, 
(Kinsinger et al., 2010; Middleton et al., 2006) whereas the remaining five studies examined 
individual cognitive domains.  Although all of the studies quantified the scores into either t-
scores or z-scores, which allowed for comparison against the population mean, they tended 
to use different measurement criteria.  Two studies defined cognitive impairment as 
performance on one neuropsychological test below the 5
th
 percentile, using a t-score (Marrie 
et al., 2005) or z-score (Jones, 2012).  However, Deloire et al. (2006) defined cognitive 
impairment as performance on two neuropsychological tests below the 5
th
 percentile of 
healthy controls, matched for age, gender and education levels.  Roberg et al. (2012), studies 
one and two, did not define neuropsychological measurement criteria.   
Middleton et al. (2006) and Roberg et al. (2012), studies one and two, compared MS 
patients’ neuropsychological performance to controls using t-tests.  They found MS patients 
performed more poorly than controls on tasks assessing speed of processing and delayed 
memory (Roberg et al., 2012, studies 1 & 2), list learning, verbal fluency, working memory 
(Roberg et al., 2012, study 1) and poorer on overall composite scores (Middleton et al., 
2006).  Deloire et al. (2006) demonstrated that 88% of MS patients performed at less than 
the 5
th
 percentile of controls on at least one test.  Marrie et al. (2005) and Jones (2012) found 
56% and 54% of patients to be impaired in one domain, respectively.  This data was not 
reported by Kinsinger et al. (2010). 
The relationship between subjective cognitive functioning and objective cognitive 
functioning 
Six of the seven studies found small to medium positive correlations between self-reported 
cognitive functioning and performance on specific tasks, finding increasing subjective 
cognitive complaints associated with decreasing cognitive performance, as measured by 
neuropsychological tests.  Roberg et al. (2012), study two,  found a small correlation 
between perceived speed of processing and performance on speed of processing tasks.  
Roberg et al. (2012), study one, found a large correlation between perceived speed of 
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processing and commission errors on an executive functioning task.  Kinsinger et al. (2010) 
found a small to medium correlation between subjective cognitive functioning and overall 
cognitive performance.  Jones (2012) found subjective cognitive functioning was correlated 
with one executive functioning task and working memory.  Marrie et al. (2005) performed 
univariate logistic regression and found a non-linear relationship between immediate 
memory, processing speed and subjective complaints; slight declines in cognitive 
impairment were associated with increased risk of subjective cognitive impairment.  This 
relationship was not significant when defining impairment by traditional means (less 5
th
 
percentile).  However, Deloire et al. (2006) only found one cognitive domain, speed of 
processing, to be correlated with one question about memory complaints.  Middleton et al. 
(2006) found no correlation between perceived global cognitive functioning and objective 
cognitive functioning.  They did, however, find a significant correlation between ‘estimates 
performance’ and objective cognitive functioning.   
The relationship between depression and fatigue, and subjective cognitive functioning 
Six of the seven studies demonstrated self-reported cognitive functioning to be associated 
with depression, reporting positive correlations. As depression levels increased, patients 
reported more problems with cognition.  However, this ranged from weak (r = .28, Roberg et 
al., 2012, study 2) to medium correlations (r = .43, Deloire et al., 2006).  A multivariate 
logistic regression demonstrated that as depression increased so did the likelihood of 
reporting subjective cognitive impairment (Marrie et al., 2005) .  Roberg et al. (2012), study 
one, did not find a significant association between depression and subjective speed of 
processing. 
Six studies reported the association between self-reported cognitive functioning and 
fatigue.  Five studies used a correlational design and found medium (r = .35, Deloire et al., 
2006) to large correlations (r = .68, Kinsinger et al., 2010) demonstrating that subjective 
cognitive complaints increased as levels of self-reported fatigue increased.   Marrie et al. 
(2005) used a multivariate logistic regression, finding increasing physical fatigue to be 
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associated with increased subjective cognitive impairment.  Jones (2012) did not report this 
data. 
The relationship between depression and fatigue, and objective cognitive functioning 
Kinsinger et al. (2010) found that neither depression nor fatigue were associated with 
objective cognitive functioning.  No other studies assessed the relationship between 
depression, fatigue and objective cognitive functioning. 
Extended analysis 
Five studies performed further analysis on the data, with three studies using multiple 
regression analysis to examine unique predictors of subjective cognitive functioning 
(Middleton et al., 2006; Roberg et al., 2012, study 1 & 2).  Kinsinger et al. (2010) and Marrie 
et al. (2005) used logistic regression analysis to examine depression and fatigue as predictors 
of subjective cognitive functioning.  Whereas, Jones (2012) used an ANOVA to examine the 
role of depression in patients categorised as ‘impaired’ or ‘unimpaired’ on 
neuropsychological tests. 
 Middleton et al. (2006) found disability, fatigue, anxiety and depression were the 
only unique predictors of subjective cognitive functioning, collectively accounting for 40% 
of the variance, when objective performance was removed.  Depression (β = .54) and anxiety 
(β = .55) accounted for the greatest unique variance. 
 Marrie et al. (2005) demonstrated that increasing physical fatigue and depression 
were both associated with increased odds of subjective impairment. 
Conversely, both Roberg et al. (2012), studies one and two,  did not find either 
depression or fatigue to uniquely account for any of the variance in subjective cognitive 
functioning.  Roberg et al. (2012), study two,  found the only variables to account for the 
unique variance in subjective processing speed, when controlling for disease duration, age 
and physical disability, was extroversion (R² = .21) and anxiety (R² = .10).  Roberg et al. 
(2012), study one, found anxiety (R² = .34) and a finger tapping task (R² = .14) to uniquely 
account for the variance in subjective processing speed.  Unlike the Marrie et al. (2005) 
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study, Roberg et al. (2012), studies one and two, did not control for objective cognitive 
performance. 
 Jones (2012) found that depressed patients reported more subjective 
cognitive difficulties, regardless of whether they are cognitively ‘impaired’ or ‘unimpaired’ 
on neuropsychological tests.   
Kinsinger et al. (2010) demonstrated that participants perceived fewer cognitive 
complaints after successful psychological treatment (t = -7.65), which improved self-
reported depression and fatigue.  Additionally, they found that as depression and fatigue 
decreased, the probability of patients becoming more accurate at perceiving their cognitive 
functioning increased. 
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Discussion 
The current review aimed to investigate MS patient’s accuracy at reporting their cognitive 
functioning when compared to their objective cognitive functioning on neuropsychological 
tests.  Additionally, both depression and fatigue were examined to determine if they were 
associated with subjective reporting of cognitive functioning.  To explore this, seven studies 
were identified and selected for inclusion.  Although this is a relatively small number of 
studies, the focus of this review was to examine the contribution of both depression and 
fatigue. 
The relationship between subjective and objective cognitive functioning  
The literature reviewed demonstrated mixed results when examining the relationship 
between self-reported cognitive symptoms and objective cognitive functioning, as measured 
by neuropsychological tasks.  Although the review generally demonstrated small to medium 
positive correlations between self-reported cognitive functioning and objective performance, 
this was confined to one or two specific neuropsychological tasks, rather than a specific 
cognitive domain.  These correlations did not tend to be domain specific, for example 
Deloire et al. (2006) only found processing speed to correlate with one question assessing 
subjective memory complaints.  Although  a large correlation was demonstrated in Roberg et 
al. (2012), study one, this correlation was between subjective speed of processing and one 
particular area (commission errors), on one executive functioning task.  Only one study 
(Roberg et al., 2012, study 2) found a domain specific correlation.  However, this correlation 
was weak.   Studies using overall neuropsychological composite scores, rather than 
examining individual cognitive domains, found small strength correlations (Kinsinger et al, 
2010) or no relationships (Middleton et al., 2006) between subjective and objective 
performance.  Marrie et al. (2005) found only slight declines in cognitive functioning were 
associated with increased reporting of subjective cognitive impairment.  The findings of this 
review suggest that MS patients are not particularly accurate at reporting their cognitive 
functioning.  Although some associations between subjective and objective cognitive 
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functioning have been found, there does not appear to be a consistent association between 
cognitive complaints in any particular domain and objective functioning in a specific 
domain. 
A number of differences in the methodology in each of the reviewed studies make 
comparisons difficult.  For instance, two studies used composite scores to measure objective 
cognitive functioning, whereas the other four studies examined individual cognitive 
domains.  Although all of the studies quantified the scores into standard scores, which 
allowed for comparison against the population mean, studies tended to use different 
measurement criteria.  The differences in definitions of cognitive impairment mean 
participants defined as ‘impaired’ in one study could be defined as ‘unimpaired’ in another 
study. 
In addition, each study used different neuropsychological tests and focused on 
different cognitive domains.  The cognitive domains thought to be most commonly affected 
in MS, memory and processing speed difficulties, were assessed by the majority of studies.  
However, there were differences between studies, for example studies assessing the same 
cognitive domain often used different neuropsychological tests.  Some studies used 
numerous cognitive tests to assess one cognitive domain, whereas other studies only used 
one individual test.  The procedure for collecting data also differed, most of the studies 
conducted face-to-face cognitive assessment, whereas Kinsinger et al. (2010) used telephone 
neuropsychological assessment.  The use of telephone assessments means it is not possible to 
determine whether all participants were tested under the same conditions, for example some 
participants may have been using aides. 
Furthermore, measures of subjective cognitive impairment were not consistent 
throughout the reviewed studies, and were limited to the cognitive domains they included.  
The majority of studies assessed subjective cognitive performance in multiple domains, 
including speed of processing, memory, concentration, attention.  The Roberg et al. (2012) 
studies focused solely on processing speed.  Only Jones (2012) examined at all of the 
cognitive domains that are thought to be affected in MS.  In addition to the PDQ, Jones 
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(2012) provided additional questions assessing language and processing speed due to the 
prevalence of these cognitive difficulties in MS population. 
As the aims of each of the studies were slightly different, this meant the population 
of MS participants differed in some studies.  Deloire et al. (2006) only recruited newly 
diagnosed MS participants who all had relapsing-remitting MS.  As Kinsinger et al. (2010) 
was examining treatment of depression, the sample only included MS patients who were 
experiencing depression.  Marrie et al. (2005)  used a sample of MS patients who were all 
experiencing cognitive difficulties.  In addition, the majority of the studies were cross 
sectional in design, making it difficult to infer causality.   
The role of depression and fatigue on subjective cognitive functioning 
The second aim of the review was to examine the role of depression and fatigue on 
subjective cognitive functioning.  At the minimum, all studies used correlational analysis to 
investigate the relationship between depression or fatigue and subjective cognitive 
functioning.  With the exception of Roberg et al. (2012), study one, all of the studies 
demonstrated that as levels of depression increased, so did subjective cognitive complaints.  
However, this relationship was only marginally associated in Roberg et al. (2012) , study 
two.   In other studies, a medium correlation was found.  A stronger association was 
demonstrated between fatigue and subjective cognitive functioning, with all studies that 
assessed this demonstrating medium to large correlations. 
Although further analysis was conducted in five studies, the difference in the aims 
and analysis makes comparisons difficult.   Studies examining unique predictors of cognitive 
functioning found contrasting results (Marrie et al., 2005; Roberg et al., 2012, study 1 & 2).   
Marrie et al. (2005) found depression and fatigue to account for the greatest unique variance, 
whereas Roberg et al. (2012), studies one and two, did not find depression or fatigue to 
uniquely account for any of the variance in subjective functioning.  Although different 
methodology was used by Middleton et al. (2006), Kinsinger et al. (2010) and (Jones, 2012) 
the results generally corroborate the findings of Marrie et al. (2005).   
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Synthesising these analyses is also complicated by the lack of reported effect sizes 
and confidence intervals.  Effect sizes could not be calculated from the existing published 
data due to the limited information reported.   
In addition to the limitations described previously, there are also additional 
considerations when examining the secondary aim.  The measures used to examine 
depression and fatigue differ from study to study.  Given the population being studied, the 
measures need to be sensitive to MS symptoms.  Measures of depression should not include 
somatic symptoms of MS, such as fatigue and decreased concentration, as this may lead to 
falsely elevated depression. Only three studies use a suitable depression measure, using the 
BDI – FS (Jones, 2012; Roberg et al., 2012), which is specifically designed to assess 
depressive symptoms in medical populations, and has also been validated within the MS 
population, and the MHI, which excludes somatic symptoms of depression (Marrie et al., 
2005).  Furthermore, measures of fatigue varied between studies and not all had been 
validated in the MS population. It should be noted that measures of fatigue and depression, 
in all studies, were screening measures and not diagnostic tests.   
In relation to the review question, three studies were found to have particular 
strengths (Jones, 2012; Marrie et al., 2005; Middleton et al., 2006) .  There were a number of 
positives about these studies including large samples of participants with varying MS 
presentations, varying disease durations, objective cognitive measures that assessed all 
domains found to be affected in MS, subjective areas that assessed a number of cognitive 
domains,  depression measures that did not include somatic symptoms (Jones, 2012; Marrie 
et al., 2005) and a control group (Middleton et al., 2006), However, there were also 
limitations to these studies with participants recruited from clinics only, potentially leading 
to a biased sample.  All of the participants in the Marrie et al. (2005) study were recruited 
due to pre-existing cognitive complaints, possibly leading to a biased sample.  In addition, 
Middleton et al. (2006) used a depression measure that included somatic symptoms of 
depression.  Furthermore, Jones (2012) did not compare subjective cognitive functioning to 
fatigue.  These studies demonstrated mixed findings when examining the relationship 
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between subjective and objective cognitive functioning, suggesting no clear relationship.  
These studies demonstrated similar findings when examining the relationship between 
depression and fatigue and subjective cognitive impairment, finding depression and fatigue 
influence subjective cognitive impairment. 
Conclusion  
This systematic review has demonstrated that there is no clear relationship between MS 
patients’ subjective and objective cognitive functioning in any particular cognitive domain.  
However, the review has shown that fatigue impacts upon this relationship, with patients 
who report greater levels of fatigue reporting increasing cognitive difficulties.  A slightly 
less consistent relationship has been found with depression.  The findings of this review have 
direct implications for clinical practice, as MS patients may potentially underestimate or 
overestimate their cognitive functioning.  This kind of discrepancy might not be identified in 
time-limited medical consultations that rely on MS patient’s subjective report of their 
cognitive functioning, when no formal neuropsychological assessments are carried out.  
Fatigue and depression should both be considered when patients are reporting cognitive 
difficulties.  In addition, there are potential therapeutic implications from this review, as the 
treatment of fatigue and depression may improve MS patient’s accuracy at reporting their 
cognitive functioning, as demonstrated previously with psychological interventions (Marrie 
et al., 2005).  Current interventions for self-reported cognitive difficulties in the MS 
population may include compensatory cognitive strategies.  However, interventions may 
prove more effective if they focus on reframing perceptions of difficulties. 
Although the studies in this review have accounted for some of the variance in 
subjective cognitive functioning, it is likely other variables influence the relationship.  In 
order for effective interventions, to improve MS patient’s accuracy at assessing their 
cognitive functioning and potentially increasing quality of life, these variables need to be 
accounted for.  A recent study by (Schmitt, Goverover, DeLuca, & Chiaravalloti, 2014) has 
implicated self-efficacy as a predictor of self-reported cognitive functioning, when 
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controlling for depression.   It therefore seems prudent to explore the relationship between 
self-efficacy and objective and subjective cognitive functioning, whilst taking into account 
the role of fatigue and depression.   
This review has also highlighted that future studies in this area should use a 
consistent approach to methodology including a uniform approach to defining cognitive 
impairment, assessing all cognitive domains associated with MS, using appropriate measures 
that have been validated in the MS population and recruiting participants with varying MS 
presentations.
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Chapter 2:  The predictive role of self-efficacy and objective cognitive 
functioning on subjective cognitive functioning and quality of life in 
Multiple Sclerosis
1
   
                                                          
1
 To be submitted to Multiple Sclerosis Journal, author guidelines can be found in Appendix H 
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Abstract 
Background:  Self efficacy, a belief in an individual’s own capabilities, has previously been 
found to play an important role in how individuals meet the challenges of health conditions. 
Objectives:  The aim of this study was to investigate whether self-efficacy is associated with 
subjective cognitive functioning and quality of life in people with Multiple Sclerosis (MS) when 
controlling for objective cognitive functioning, fatigue, depression and anxiety.    
Methods: Forty five MS participants completed neuropsychological tests and self-report 
questionnaires measuring subjective cognitive functioning, quality of life, self-efficacy, 
depression, anxiety and fatigue.  
Results: Correlational analysis showed associations between self-efficacy, depression, anxiety, 
fatigue, MS duration, objective cognitive functioning and subjective cognitive functioning.  
Associations were also demonstrated between depression, self-efficacy, anxiety, fatigue and 
quality of life.  Hierarchical regression analysis showed self-efficacy is a significant predictor of 
subjective cognitive functioning and quality of life even after controlling for age, MS duration, 
depression, anxiety, fatigue and objective cognitive functioning.  
Conclusion: This study has demonstrated that self-efficacy is an important predictor of 
subjective cognitive functioning and quality of life.  Important implications in relation to 
clinical practice are discussed. 
Keywords  
Anxiety, cognition, depression, fatigue, multiple sclerosis, objective cognitive functioning, 
quality of life, subjective cognitive functioning. 
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Introduction 
Cognitive decline is a common symptom in Multiple Sclerosis (MS), with approximately 50% 
of people experiencing cognitive difficulties 
1, 2
.  Research has shown that cognitive dysfunction 
in people with MS has a significant impact on daily living, lifestyle, social functioning, overall 
quality of life 
2
 and employment status 
3
.  However, discrepancies have been noted between 
self-reported cognitive functioning and objective assessments of functioning as measured by 
neuropsychological assessment 
4-12
.  These studies have generally demonstrated that people with 
MS are not particularly accurate at reporting their cognitive functioning, finding either no 
relationship or weak relationships between subjective cognitive functioning and one or two 
specific cognitive tests.  There does not appear to be a consistent association between cognitive 
complaints in any particular cognitive domain and objective functioning in a specific domain 
4-
12
.  This kind of discrepancy is unlikely to be identified in routine medical consultations, 
including those in specialist MS services, when no formal neuropsychological assessments are 
carried out and clinicians rely on subjective reports.   
Several studies have shown levels of self-reported cognitive functioning to be associated with 
symptoms of depression but not with objective assessments of cognitive functioning 
6, 13
, in that 
people with MS experiencing depression report greater cognitive difficulties when compared to 
their objective functioning.  Furthermore, Kinsinger et al. 
12
 found fatigue, along with 
depression, to positively correlate with subjective cognitive complaints.  However, depression 
and fatigue were not associated with objective cognitive performance.  In addition to depression 
4, 5, 7-10, 12-15
 and fatigue 
9, 10, 12, 14, 15
, self-reported cognitive functioning has also been shown to be 
associated with anxiety 
15
 and self-efficacy 
16
.  These studies demonstrated that subjective 
cognitive complaints increased as levels of depression, fatigue and anxiety increased, and self-
efficacy decreased.  The implication of these results is that depression, anxiety, self-efficacy and 
fatigue may influence MS patients’ ability to accurately perceive their cognitive performance.  
Increased depression and fatigue are also associated with reduced quality of life in people with 
MS 
17
. 
37 
 
Self-efficacy, which can be described as an individual’s belief about their ability to manage 
specific situations or conditions 
18
, has been shown to play an important role in the MS 
population.  Schmitt et al. 
16
 found that self-efficacy was a significant predictor of self-reported 
physical, cognitive and social functioning, after controlling for functional impairment and 
depression.  Higher levels of self-efficacy were associated with better self-reported physical and 
cognitive functioning.  In addition, self-efficacy was associated with health related quality of 
life.  However this study did not measure or control for objective cognitive functioning or 
fatigue.   
Previous research has demonstrated that self-efficacy is a predictor of psychological adjustment 
to MS, in that self-efficacy is positively associated with psychological wellbeing and predicts 
higher levels of social activity and self-esteem 
19
.  Furthermore, Riazi et al. 
20
 found increased 
self-efficacy predicted improved health status in rehabilitation settings.  In addition, higher 
levels of self-efficacy are associated with increased motivation, psychological wellbeing, 
adherence with treatment and self-reported quality of life 
21
.  MS wellness programs have been 
developed to promote health and quality of life 
18
.  These wellness programs have included a 
component addressing self-efficacy.  Ng et al. 
18
 found that over the course of one such wellness 
program, self-efficacy and quality of life improved.    
Although previous research has identified a relationship between self-efficacy and subjective 
cognitive functioning, and between self-efficacy and quality of life, this research has failed to 
examine the role of objective cognitive functioning and fatigue.  The purpose of the study was 
to examine the relationship between objective and subjective cognitive functioning in a group of 
people with MS, using a subjective questionnaire measure and neuropsychological tests.  In 
addition, the study aimed to examine if self-efficacy predicted subjective cognitive functioning 
and quality of life, whilst controlling for other variables previously found to be related to 
subjective cognitive functioning.  It is hypothesised that self-efficacy will predict subjective 
cognitive functioning and quality of life when objective cognitive functioning, MS duration, 
age, depression, anxiety and fatigue are controlled for. 
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Materials and method 
 A total of 45 patients (29 females, 16 males), with clinically definite MS were recruited from 
routine clinics at a North West England Neurology Hospital (Appendix D & E).  Patients were 
excluded if they were currently experiencing an episode of relapse and if they had other chronic 
medical conditions that might have contributed to cognitive impairment (e.g. epilepsy).  
Demographic information was collected including age, gender, years in education, duration of 
MS and MS subtype.  
Measures  
Dependent variables. Subjective cognitive functioning was measured using the Perceived 
deficits questionnaire (PDQ 
22
).  It is a 20 item questionnaire, consisting of questions that assess 
subjective memory, attention, and planning.  Total scores range from 0 - 80, with higher scores 
indicating greater subjective cognitive impairment.  Internal consistency has been measured at α 
= .95 in an MS population 
23
. 
Quality of life was measured using the WHO Quality of Life – BRIEF (WHOQOL 24), a 26 item 
questionnaire rated on a five point scale.  Higher scores indicate greater quality of life.  Internal 
consistency in an MS population has been measured at between α = .63 and α = .81 25. 
Independent variables.  Composite objective cognitive functioning scores (COCFS) was 
assessed using standardised neuropsychological tests (Appendix F).  The tests were selected as 
they measure cognitive domains frequently affected in MS 
26
; digit span from the Wechsler 
Adult Intelligence Scale-IV (concentration and working memory), visual reproduction from the 
Wechsler Adult Memory Scale-IV (visual memory), Symbol Digit Modalities Test (SDMT; 
information processing speed), California Verbal Learning Test-II (CVLT; verbal learning and 
memory), Hayling from the Hayling and Brixton (Executive Functioning) and verbal fluency 
from the Delis-Kaplan Executive Functioning System.  Raw scores were compared against 
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published normative population data for each test to derive age-adjusted standard scores. These 
were then converted into T scores to allow comparisons between different tests. 
The Hospital Anxiety and Depression Scale (HADS 
27
) was used to measure psychological 
distress.  The HADS is an anxiety and depression screening measure, for people with physical 
ill health.  Total scores range from 0 – 21 for both anxiety and depression, with higher scores 
indicating greater levels of depression or anxiety.  The HADS does not ask questions about 
somatic symptoms such as fatigue and sleep, therefore avoiding falsely elevated scores in 
people with MS.  Atkins et al. 
28
 report good levels of internal consistency within the MS 
population. 
The Fatigue Severity Scale (FSS 
29
) was used to assess the severity of fatigue and the impact of 
fatigue on activities and lifestyle.  Total scores range from 9 – 63, with higher scores indicating 
greater fatigue.  Internal consistency has been measured at α = .81 in an MS population and α = 
.81 in a healthy population 
29
.   
Self-efficacy was measured using the General Self-Efficacy Scale (GSES 
30
).  It is a 30 item 
scale that includes a general self-efficacy subscale and a social self-efficacy subscale.  For the 
purposes of this study, only general self-efficacy scores were used as it reflects a general 
overview of functioning, rather than being limited to social self-efficacy.  It contains 17 items, 
rated on a five point scale.  Higher scores indicate greater self-efficacy.  Internal consistency has 
been measured at α = .85 30.    
Control variables.  Age and MS duration. 
Procedure  
Ethical approval was obtained from Greater Manchester West National Research Ethics Service.  
Participants were informed about the study during their routine MS clinic appointments and 
invited to participate.   Neuropsychological testing and questionnaires were either completed at 
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a further clinic appointment or at the participant’s home.  During the appointment, participants 
completed the cognitive assessments and the self-report questionnaires. 
Data analysis  
Data analysis was conducted using SPSS (21) statistical software.  Correlational analysis was 
used to explore the relationship between PDQ and hypothesised variables of interest.  This 
analysis was repeated exploring the relationship between quality of life (QoL) and hypothesised 
variables of interest.  Two hierarchical multiple regression analyses were conducted; one to 
examine the relationship between self-efficacy and PDQ after controlling for age, MS duration, 
fatigue, depression, anxiety, executive functioning (EF) and COCFS, and one to examine the 
relationship between self-efficacy and quality of life after controlling for age, MS duration, 
fatigue, depression, anxiety, EF and COCFS.   
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Results 
A total of 45 participants with MS were included in the study.  The participants were composed 
of predominantly females (N = 29), reflecting the MS population.  Patients ranged in age from 
23 - 73 (M = 46.20).  In terms of MS subtypes, 78% had relapsing-remitting, 7% had secondary 
progressive and 15% had primary progressive.  Patients years in education ranged from 11 – 21 
(M = 14.61) and their length of illness ranged from 1-32 years (M = 6.84) (table 1). 
Objective neuropsychological tests represented a wide range of tests examining different areas 
of cognitive functioning.  As participants’ performance could vary from test to test, it could not 
be assumed that a simple averaging of these tests would represent a valid and reliable measure 
of their overall objective cognitive functioning. However, in order to simplify the analysis of 
objective cognitive function, it was deemed appropriate to attempt a form of data 
reduction.  The method chosen for this was a Principle Component Analysis (PCA) of the eight 
neuropsychological tests.   
Prior to preforming PCA, the suitability of the data for factor analysis was assessed.  Inspection 
of the correlation matrix revealed the majority of the coefficients were above .5.  A Direct 
Oblimin rotation was used as it was assumed that any derived factors would be oblique rather 
than orthogonally related.  The Kaiser Meyer-Olkin value was .844, exceeding the 
recommended value of .6 and Bartlett’s test of Sphericity reached statistical significance 
supporting the factorability of the correlation matrix. 
PCA revealed the presence of two factors with eigenvalues, exceeding 1, explaining 56% and 
13% of the variance respectively.   Seven components loaded onto factor 1, (digit span, SDMT, 
immediate and delayed visual reproduction, CVLT, verbal fluency, category fluency) and one 
component loaded on factor 2 (executive functioning).  Therefore, for the purposes of the 
analysis the Composite Objective Cognitive Functioning Score  (COCFS) was computed using 
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the average T-scores for the seven tests loading onto factor 1 and executive functioning scores 
were used unchanged.     
Correlations  
Pearson’s R was used to conduct correlational analyses between tests of cognition, age, MS 
duration, measures of fatigue, emotion, self-efficacy, subjective cognitive functioning and 
quality of life.  PDQ was significantly associated with quality of life (r = -.65, p < .001), self-
efficacy (r = -.64, p < .001), depression (r = .60, p < .001), anxiety (r = .59, p < .001), fatigue (r 
= .42, p < .001), MS duration (r = .38, p < .001), and COCFS (r = -.35, p < .05).  In addition to 
PDQ, quality of life was associated with depression (r = -.65, p < .001), self-efficacy (r = .61, p 
< .001), anxiety (r = -.54, p < .001) and fatigue (r = -.48, p < .001).  Correlation coefficients can 
be seen in table 1.   
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Table 1. Correlation coefficients between tests of cognition, age, MS duration, measures of fatigue, emotion, self-efficacy, subjective cognitive functioning 
and quality of life 
Variables Mean SD 1 2 3 4 5 6 7 8 9 
1.Age 46.20 12.61          
2.Duration  6.84 7.22  .08        
3.FSS 42.60 14.75  .18  .18       
4.Depression 6.40 4.35 -.12  .15  .45**      
5.Anxiety 7.82 4.39 -.27  .35*  .24  .72**     
6.GSE 59.47 13.09  .11 -.09 -.20 -.63** -.49**      
7.EF 45.73 10.07 -.17 -.17 -.29  .00  .04  .05    
8.COCFS 47.30 9.14  .01 -.37* -.16 -.14 -.18  .06  .34*   
9.PDQ 35.29 17.64 -.14  .38**  .42**  .60**  .59** -.64** -.23 -.35*  
10.QoL 258.67 6.99 -.05 -.25 -.48** -.65** -.54**  .61**  .10  .15 -.65** 
** Correlations significant at the 0.01 level (2-tailed) * Correlations significant at the 0.05 level (2-tailed)                                                                                          
Note. COCFS: Composite Objective Cognitive Functioning Score; Duration: MS duration; EF: Executive Functioning; FSS: Fatigue Severity Scales; 
GSE: General Self-Efficacy Scale; PDQ: Perceived Deficits Questionnaire; QoL: Quality of Life Questionnaire                                                                                   
4
3 
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Subjective cognitive functioning 
Preliminary analyses were conducted to ensure no violations of the assumptions of normality, 
linearity and homoscedasticity (Appendix G).  Hierarchical multiple regression was used to 
assess the ability of self-efficacy to predict subjective cognitive functioning after controlling for 
the influence of age, MS duration, depression, anxiety, fatigue, EF and COCFS.  Age and MS 
duration were entered into step 1, explaining 18% of the variance of subjective cognitive 
functioning.  After entry of fatigue and HADS scores, step 2 explained 50% variance.  After 
entry of EF and COCFS scores in step 3, the total variance explained by the model as a whole 
was 54%, F (7, 37) = 6.28, p <. 001.   However, EF and COCFS did not make a statistically 
significant contribution.  Self-efficacy explained an additional 11% of the variance in subjective 
cognitive functioning, after controlling for age, MS duration, fatigue, anxiety, depression, EF 
and COCFS, R squared change = .11,  F change (1, 36) = 11.80, p = .002.  In the final model, 
only self-efficacy (beta = -.44, p = .002) was statistically significant (table 2). 
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Table 2. Hierarchical Regression Analysis for PDQ (N = 45) 
Variable Beta SE(B) β Adjusted R² 
Step 1    .14* 
Age -.24  .19 -.17  
MS Duration   .97  .34  .39  
Step 2    .44** 
Age -.14  .17 -.09  
MS Duration   .58  .31  .24  
FSS  .24  .16  .20  
Depression 1.28  .75  .32  
Anxiety  .83  .75  .21  
Step 3    .46** 
Age -.15  .17 -.10  
MS Duration   .42  .32  .17  
FSS  .17  .16  .15  
Depression 1.32  .73  .33  
Anxiety  .87  .74  .22  
COCFS -.24  .24 -.13  
EF -.26  .22 -.15  
Step 4    .58** 
Age -.13  .15 -.09  
MS Duration   .41  .28  .17  
FSS  .23  .14  .19  
Depression  .20  .72  .05  
Anxiety  .74  .65  .19  
COCFS -.29  .22 -.15  
EF -.18  .19 -.10  
GSE -.59  .17 -.44*  
** p < .001 * p < .05 Note. COCFS: Composite Objective Cognitive Functioning Score; EF: Executive Functioning; 
FSS: Fatigue Severity Scale; GSE: General Self-Efficacy Scale; PDQ: Perceived Deficits Questionnaire 
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Quality of life  
Hierarchical multiple regression was used to assess the ability of self-efficacy to predict 
subjective quality of life after controlling for the influence of age, MS duration, depression, 
anxiety, fatigue and objective cognitive functioning.  Age and MS duration were entered into 
step 1, explaining 7% of the variance of subjective cognitive functioning.  After entry of fatigue 
and HADS scores, step 2 explained 51% variance.  After entry of EF and COCFS scores in step 
3, the total variance explained by the model as a whole was still 51%, F (7, 37) = 5.40, p <. 001.   
COCFS did not make a statistically significant contribution.  Self-efficacy explained an 
additional 8% of the variance in subjective cognitive functioning, after controlling for age, MS 
duration, fatigue, HADS, EF and COCFS, R squared change = .08,  F change (1, 36) = 6.61, p = 
.014.  In the final model, only self-efficacy (beta = .36, p = .01) was statistically significant 
(table 3). 
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Table 3. Hierarchical Regression Analysis for QoL (N = 45) 
Variable Beta SE(B) β Adjusted R² 
Step 1    .02 
Age -.16  .72 -.03  
MS Duration -2.11 1.27 -.25  
Step 2    .44** 
Age -.53  .59 -.11  
MS Duration  -.68 1.06 -.08  
FSS -.88  .55 -.21  
Depression -6.14 2.57 -.44*  
Anxiety -2.34 2.57 -.17  
Step 3    .41** 
Age -.52  .61 -.11  
MS Duration  -.67 1.15 -.08  
FSS -.86  .58 -.21  
Depression -6.18 2.64 -.44  
Anxiety -2.36 2.65 -.17  
COCFS -.04  .88 -.01  
EF  .13  .79  .02  
Step 4    .49** 
Age -.56  .57 -.12  
MS Duration  -.65 1.08 -.08  
FSS -1.03  .55 -.25  
Depression -2.99 2.76 -.21  
Anxiety -1.99 2.47 -.14  
COCFS  .09  .82  .02  
EF -.09  .74 -.02  
GSE 1.68  .66  .36*  
** p < .001, * p < .05 Note. COCFS: Composite Objective Cognitive Functioning Score; EF: Executive 
Functioning; FSS: Fatigue Severity Scale; GSE: General Self-Efficacy Scale; QoL: Quality of Life 
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Discussion 
The results of this study demonstrated significant relationships between subjective cognitive 
functioning and self-efficacy, depression and anxiety, with a large effect size.  In addition, 
significant relationships, with a medium effect size, were demonstrated between subjective 
cognitive functioning and fatigue and objective cognitive functioning (COCFS).   MS 
participants who reported more subjective cognitive difficulties also reported greater levels of 
depression, anxiety and fatigue.  They also performed poorer on objective cognitive tests and 
reported lower levels of self-efficacy.   In addition, self-efficacy, depression, anxiety and fatigue 
were shown to be associated with quality of life in our sample of participants with MS.  
Participants reporting greater self-efficacy and fewer symptoms of depression, anxiety and 
fatigue, reported better quality of life.  Furthermore, self-efficacy was shown to be a significant 
predictor of self-reported cognitive difficulties and quality of life even after controlling for age, 
MS duration, depression, anxiety, fatigue and objective cognitive functioning. 
The results of this study corroborate the findings of a number of studies demonstrating 
associations between subjective cognitive functioning and depression, anxiety 
10, 12, 14, 15, 31
 
fatigue 
15, 31
 and self-efficacy 
16
.  Previous studies have demonstrated mixed findings when 
examining the relationship between subjective cognitive functioning and objective cognitive 
functioning, using composite scores.  The findings of this study are contrary to the findings of 
Middleton et al. 
10
,  who found no relationship.  This study supports the findings of Kinsinger et 
al. 
12
 who found a weak relationship. 
This study corroborates the findings of previous studies showing self-efficacy to be associated 
with subjective cognitive functioning 
16
 and quality of life 
16, 18, 21
.  This study found that self-
efficacy, fatigue, anxiety and depression were all significant predictors of subjective cognitive 
functioning and quality of life.  However, self-efficacy was the only variable to make a unique 
contribution to both dependant variables when all the other variables were controlled for.  
Although objective cognitive functioning was associated with subjective cognitive functioning, 
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this did not make a significant contribution in the regression model and was not associated with 
quality of life.   
This study has demonstrated that self-efficacy is a greater predictor of subjective cognitive 
functioning and quality of life than objective cognitive functioning, depression, anxiety or 
fatigue.  This has important implications for clinical practice.  This research has further 
demonstrated the importance of a number of variables that are associated with self-appraisal of 
cognitive functioning, that are not strongly associated with objective cognitive performance.  
Clinically, this highlights the need for specialist assessments of cognitive functioning and 
further assessments of self-efficacy, mood and fatigue.  Specialist assessments will enable 
clinicians to develop meaningful formulations about factors underlying inaccurate self-
appraisals of cognitive functioning, allowing clinicians to provide feedback to clients about 
what factors, other than objective functioning, may contribute to perceived cognitive 
difficulties.  People with MS may be reassured to know that their subjective cognitive 
difficulties could be attributed to other factors, such as low self-efficacy, and not necessarily 
due to MS related neurological change.   
Additionally, self-efficacy could be targeted for intervention.   A previous study 
12
 has 
demonstrated that interventions aimed at improving depression and fatigue show some success 
at improving MS patients’ accuracy at perceiving their cognitive functioning.  However, the 
findings of this study would suggest that targeting self-efficacy for intervention might be more 
effective as it was a greater predictor of both subjective cognitive functioning and quality of 
life, rather than mood or fatigue.  Interventions aimed at improving self-efficacy could 
potentially improve MS patients’ accuracy at appraising and reporting their cognitive 
functioning and improve their quality of life.  Self-efficacy has previously been found to be a 
predictor of psychological adjustment to MS 
19
, and has been targeted for intervention 
18, 20
.  
Improvements in self-efficacy, using self-management programs 
18, 32
 and social cognitive 
wellness programs 
33
, have been associated with improvements in quality of life.  These 
improvements have been maintained at six month follow up.  Additionally, increasing self-
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efficacy has also been found to be associated with lower levels of depression, anxiety 
34, 35
 and 
fatigue 
34
.  To the author’s knowledge, no longitudinal research studies have examined whether 
targeting self-efficacy for intervention is related to MS patients’ improved accuracy at reporting 
cognitive functioning. 
There are a number of limitations to the present study.  There was a small sample size in this 
study, in order to increase power, the sample size would need to be increased (Appendix E).  
Additionally, participants were only recruited from MS clinics and there was a short disease 
duration (M =6.95) potentially leading to a biased sample.  This study was also a quasi-
experimental design and used correlational analysis, making it difficult to ascertain causality.  
Future research would benefit from longitudinal research to address the issue of causality.   
In sum, this study has demonstrated that self-efficacy is a significant predictor of subjective 
cognitive functioning and quality of life, even after controlling for objective cognitive 
functioning, age, MS duration, depression, anxiety and fatigue.  Future research would benefit 
from longitudinal studies targeting self-efficacy in intervention studies.  This would help 
determine whether improvements in self-efficacy lead to improved accuracy at appraising 
cognitive functioning and improved quality of life in people with MS.    
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Participant information sheet - People with Multiple Sclerosis 
 
Title of Project: Investigating thinking and memory impairment and wellbeing in people 
with Neuromyelitis Optica (NMO), Multiple Sclerosis and healthy controls 
 
You are being invited to take part in a research study investigating memory, thinking and 
wellbeing in people with Neuromyelitis Optica (NMO), Multiple Sclerosis (MS) and people 
with no neurological condition. 
 
The study consists of completing several thinking and memory tasks and some 
questionnaires. The study will take between approximately one hour and one hour thirty 
minutes to complete.   
 
Before you decide to take part it is important that you understand why the research is being 
done and what it will involve.  Please take the time to read the following information 
carefully and discuss it with others if you wish.   
 
What is the purpose of this study? 
Neuromyelitis Optica is a degenerative condition that may cause blindness and paralysis. For 
many years it was considered as a type of MS but as there is now a better understanding of 
differences in symptoms and treatments then it is now important to further investigate how 
these conditions differ and what life is like for people living with them. A symptom 
mentioned commonly in both MS and NMO is thinking and memory difficulties; including 
language, concentration, attention, memory and also changes in mood.  
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This study will examine these symptoms in a group of people with MS, a group of people 
with NMO and a group of people with no neurological condition to act as a control group 
and help better understand differences in  thinking and memory and mood symptoms in 
people with MS or NMO. 
 
The study aims to involve both people who are experiencing difficulties and people who are 
not, so that we can develop a better understanding of the types of difficulties that different 
people experience and how common these difficulties are. In addition, we will be asking 
questions related to your quality of life and how you view your MS, as this can sometimes be 
linked to how people experience and manage any difficulties they may have.  
 
Do I have to take part? 
It is up to you to decide to join the study. We will describe the study and go through this 
information sheet. If you agree to take part, we will then ask you to sign a consent form. You 
are free to withdraw at any time, without giving a reason. This would not affect the standard 
of care you receive. 
 
What will happen if I consent to take part?  
You will be asked to complete a set of tests that will take approximately an hour and a half. 
 
You will be asked to complete a series of thinking and memory tasks that investigate your 
thinking, memory, concentration and language. You will also be asked to complete 
questionnaires that relate to symptoms you might experience and broader aspects of your 
wellbeing such as mood and symptoms. 
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These tasks take place at the Walton Centre or we can try to arrange to see you at home if 
this is preferable to you. Travel expenses will not be paid as it is hoped that these visits can 
be completed on the same day as your regular clinic appointments at the Walton Centre. If 
this is not possible then a researcher can visit you at your home. 
Why is this research useful? 
There is currently little research that helps to inform our understanding of the relationships 
between thinking processes, and emotional and social wellbeing of people with MS and 
NMO. Understanding more about this can then help in the management of MS and NMO 
and inform how health care services can be improved. 
 
What will happen if I don’t want to carry on? 
You are free to withdraw at any time from the study without giving a reason and without it 
affecting your future care. If you begin to complete the tests and decide you no longer wish 
to continue then you can stop at any time. If you chose to withdraw from the study any 
identifiable data will be destroyed and all non-identifiable data will be retained in the study. 
 
Complaints 
If you have a concern about any aspect of this study, you should contact the researchers on 
the details below and they will do their best to answer your questions. If you remain unhappy 
and wish to complain formally, you can do so in accordance with the NHS complaints 
procedure by contacting Research Officer Rebecca McDonald on 01515298006. 
 
What are the possible disadvantages and risks of taking part? 
We are aware that people with MS often experience fatigue (both thinking and memory and 
physical). If you feel fatigued at any point then you can take a break or postpone the testing 
until another time. If you do not feel up to taking part in testing due to ill health then please 
just let the researcher know and testing can be postponed.  
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If you are currently experiencing a relapse then you will not be able to participate until you 
are no longer having a relapse. 
 
It is possible that you may find it upsetting to think about your quality of life or feelings and 
emotions. Should you wish to stop the study you can do so immediately. Should you wish to 
skip a question on a questionnaire this is also fine.  
 
What are the benefits of taking part? 
Many people with neurological conditions report that there is a lack of information for both 
patients and health care professionals on the experience of living with these conditions and 
specifically on thinking and memory difficulties. This study aims to add information on this 
under-researched area and contribute to the improvement of care for people affected by 
neurological conditions.  
 
There are however no direct benefits to taking part. You will not receive personalised 
feedback from this testing as it is not a complete clinical assessment, however general 
information on cognition and mood can be provided.  
 
Will my taking part be kept confidential? 
All information you provide will be treated and stored confidentially, however if you told us 
anything that raised concerns about your safety or the safety of a vulnerable other then we 
would have to break confidentiality and pass this information on to the appropriate 
organisation. In this situation you would be made aware of what information would be 
reported and to whom. 
 
Some data may be used from your medical records so that we do not ask you to answer 
questions that we already have information on. This data will only be accessed by members 
of your clinical care team and will remain confidential.  
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The consent form containing personal information will be locked in a secure place, and only 
the research team will have access to it. Any data and written results will be anonymised in 
accordance with the Data Protection Act 1998.  
 
What will happen to the results of the study? 
The results of the study will be used to inform future research and to inform the management 
of MS and NMO and the types of services that would best support people’s needs.  
 
The data will be collected and anonymised so that your results cannot be identified and 
analysed to write up for peer reviewed journals and for presentation at international 
conferences.  The findings will also be written up in a newsletter and available to all patients.   
 
Who is organising and funding this research? 
This research is organised and funded by The Walton Centre for Neurology and 
Neurosurgery. 
 
Who has reviewed this study? 
This study has been reviewed by NRES Committee North West-Greater Manchester West 
12/NW/0763. 
 
Finding out more before deciding 
If you would like more information on taking part in research in general please contact 
Patient Advice and Liason Services (PALS) in the Customer Care Team: 
Customer Care Team,  
The Walton Centre NHS Foundation Trust,  
Lower Lane,  
Fazakerley,  
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Liverpool  
L9 7LJ  
0151 529 5530 or 0151 529 6100 
Customer.CareTeam@thewaltoncentre.nhs.uk 
 
If you would like to discuss this study further or if there are any questions you would like to 
ask, please contact the lead Clinical Neuropsychologist Dr Phil Moore at 
The Walton Centre NHS Foundation Trust, 
Jubilee House, 
Longmoor Lane, 
Fazakerley 
L9 7LJ 
Telephone: 0151 529 5693 
Thank you for taking the time to read this information sheet.  
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CONSENT FORM for people with Multiple Sclerosis 
Title of Project: Investigating cognitive function and wellbeing in people with 
Neuromyelitis Optica, Multiple Sclerosis and healthy controls 
 
Name of Lead Researcher:  Dr Phil Moore                              Please initial box 
 
1. I confirm that I have read and understand the information sheet for the above study. 
I have had the opportunity to consider the information, ask questions and have had 
these answered satisfactorily. 
 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected. 
 
 
 
 
3. I understand that relevant data collected during the study, may be looked at by 
individuals from regulatory authorities or from the NHS Trust, where it is relevant to 
my taking part in this research. I give permission for these individuals to have access 
to this data. 
                  
 
 
 
4. I agree that if I disclose information regarding my safety and the safety of 
vulnerable others then this information will have to be disclosed to the relevant 
authorities. 
 
 
 
5. I agree to take part in the above study. 
 
 
 
 
 
 
Name of Participant Signature Date 
________________________ ___________________ ___________ 
Researcher Signature Date 
________________________ ___________________ ___________ 
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Table 1 
Summary of studies included in the review  
Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
Delorie,  
Bonnet,  
Salort,  
Arimone,  
Boudineau 
Petry & 
Brochet 
(2006) 
Cross-
sectional  
Case 
control  
57 Age: M = 
37.17 
 
Gender: 75% 
female 
 
MS duration 
(years): M = 
2.10 
 
 
RR: 
100% 
Community 
 
Yes  
N = 44 
SRT  
SPART  
SDMT  
PASAT  
WLG  
Stroop  
Similarities  
(WAIS‐R)  
BNT  
RFF  
SEP-59 MADRS 
UKNDS 
One cognitive 
domain, speed of 
processing correlated 
with one question 
about memory 
complaints on 
MSQOL (r = .31,   
p < .02) 
 
UKNDS correlated 
significantly with 
SEP-90 (r = .35,   
p < .001) 
 
MADRS correlated 
significantly with 
UKNDS (r = .43, 
Newly diagnosed MS 
patients only  
 
All participants had RR 
MS 
 
Not all subjective 
domains assessed  
 
Depression measure,   
includes somatic 
symptoms  
 
All RR 
 
French participants – 
generalisable?  
  
6
7
 
Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
 p < .01) 
 
Jones 
(2012) 
Cross-
sectional  
 
82 Age: M  = 
51.60 
 
Gender: 60% 
female 
 
MS duration 
(years):  M = 
18.33 
 
RR: 
43%  
 
SP: 
45%  
 
PP: 
3.7% 
Clinic No CVLT II 
Digit Span (WA
IS IV) 
SDMT 
Animal fluency 
Stroop 
BJLOT 
PDQ with 
additional 
domains 
assessed 
BDI-FS 
FSS 
Significant 
relationship between 
PDQ and Stroop (r  = 
-.36,  p < .001) and 
PDQ and digit span (r 
= -.26, p < .01) 
 
Relationship between 
fatigue and PDQ is 
not reported 
 
BDI-FS correlated 
significantly with 
PDQ (r = .42, p < 
.001) 
 
No control group  
 
Fatigue not included in 
the analysis 
 
Long MS duration 
 
Comparatively high 
mean EDSS scores, 
indicating moderate to 
severe disability 
Kinsinger 
& Lattie 
Longitudin
al  
127 Age:  M = 
47.96 
RR/S
P/PR: 
Community 
and clinic 
No COWAT  
Digit Span &  
PDQ HDRS 
(telephone 
PDQ correlated with 
objective cognitive 
MS patients with 
severe cognitive 
  
6
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Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
(2010) RCT  
Gender: 77% 
female 
 
MS duration 
(years):  M = 
11.24  
 
89%,  
 
PP: 
10%,  
 
Letter‐Number  
sequencing (W
AIS‐III) 
CVLT‐II  
version) 
MFIS 
 
performance at pre (r 
= -.23, p < .01) and 
post treatment (r = -
.37, p < .01) 
 
PDQ correlated with 
MFIS at pre (r = .67, 
p < .001) and post 
treatment (r = .68, p 
< .001) 
 
PDQ correlated with 
HDRS at pre (r = .37, 
p < .001) and post 
treatment (r = .45, p 
< .001) 
 
impairment were 
excluded 
 
All patients 
experiencing 
depression  
 
Neuropsychological 
tests were administered 
via telephone  
 
No objective measure 
of processing speed 
 
Depression measure - 
includes somatic 
symptoms 
Marrie, 
Chelune, 
Miller & 
Cross-
sectional  
Correlation 
136 Age:  M = 
45.65 
 
RR: 
71%  
 
Clinic No WAIS   
WMS  
PDQ MHI 
MFIS 
Multivariate logistic 
regression 
demonstrated subtests 
All participants had 
subjective cognitive 
complaints  
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Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
Cohen 
(2005) 
Gender: 69% 
female 
 
MS duration: 
not stated 
 
SP/P
P: 
29% 
of WAIS and WMS 
are associated with 
being subjectively 
impaired independent 
of emotional status, 
physical disability, 
fatigue and age  
 
Increasing physical 
fatigue was 
associated with 
increased odds of 
subjective 
impairment 
 
Poor emotional status 
was associated with 
increased odds of 
subjective 
impairment 
 
Depression measure – 
very short screening 
measure (4 questions) 
  
7
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Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
Middleton,
Denny, 
Lynch & 
Parmenter 
(2006) 
Cross-
sectional 
Case 
control  
221 Age:  M = 
44.8 
 
Gender: 74% 
female 
 
MS duration 
(years):  M = 
6.5 
 
RR: 
65%  
 
SP: 
21%  
 
PP: 
12%  
 
PR: 
2% 
Clinic Yes  
N = 31  
TOL  
CVLT‐II  
PASAT  
SRT  
WLG 
CFQ 
Performance 
estimates 
CES-D 
FSS 
No correlation was 
found between CFQ 
and objective 
cognitive functioning.   
 
CFQ significantly 
correlated with FSS 
(r = .41, p < .001) 
 
CES-D significantly 
correlated with CFQ 
(r = .52, p < .001) 
 
CFQ does not assess all 
cognitive domains 
associated with MS 
 
Depression measure, 
includes somatic 
symptoms 
Roberg 
Bruce, 
Lovelace 
& Lynch 
(2012)  
– study 1 
Cross-
sectional  
Correlation 
40 Age:  M = 
48.58 
 
Gender: 85 % 
female  
 
MS duration 
RR: 
80% 
 
SP: 
18% 
 
PP: 
Community Yes 
N = 25 
SDMT 
Stroop 
PASAT 
LNS 
AVLT 
COWAT 
CPT II 
PSDS CMDI 
MFIS 
PSDS associated with 
commission errors on 
CPT II (r = .51, p < 
.001) and motor 
slowing on FTT (r = -
.35, p < .05) 
 
Only subjective 
cognitive domain 
assessed was speed of 
processing 
 
Depression measure – 
includes somatic 
  
7
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Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
(years):  M = 
11.53 
 
2% FTT PSDS significantly 
associated with 
fatigue (r = .54, p < 
.001) 
 
No association 
between PSDS and 
depression 
 
symptoms 
 
Large proportion of 
females  
Roberg, 
Bruce, 
Lovelace 
& Lynch 
(2012) 
 – study 2 
Cross-
sectional 
Correlation 
79 Age:  M =  
47.1 
 
Gender: 90 % 
female 
 
MS duration 
(years):  M = 
10.96 
 
RR: 
90% 
 
SP: 
10% 
 
 
Clinic Yes  
N = 20 
SDMT 
Stroop 
LNS 
AVLT 
(modified) 
PSDS BDI-FS 
MFIS 
More self-reported 
processing speed 
difficulties only 
marginally associated 
with Stoop (r = -.27, 
p = .016) and SDMT 
(r = -.28, p = .014) 
 
PSDS significantly 
associated with 
fatigue (r = .57, p < 
All participants 
recruited for 
medication-adherence 
study, presumably all 
taking medication 
 
Only subjective 
cognitive domain 
assessed was speed of 
processing 
 
  
7
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Study Study type 
and design 
N Characteristics Type 
of 
MS 
Recruited 
from 
Control 
group 
Objective 
cognitive tests 
Subjective 
cognitive 
measure 
Depression   
and fatigue 
measure 
Findings Limitations 
.001)  
 
PSDS marginally 
associated with 
depression (r = .28, p 
= .013) 
 
Stepwise regression 
demonstrated only 
extroversion (R² = 
.21, p = <.001) and 
trait anxiety (R²  = 
.10, p = <.001) 
accounted for unique 
variance in PSDS 
Large proportion of 
females 
 
Limited objective 
cognitive domains 
assessed. 
Note. AVLT = Auditory Verbal Learning Test; BJLOT  = Benton Judgement Line Orientation Test; BNT = Boston Naming Test; BDI – FS = Beck Depression Inventory – Fast Screen; CES-D = Centre for 
Epidemiologic Studies – Depression Questionnaire; CFQ = Cognitive Failures Questionnaire, CMDI = Chicago Multiscale Depression Inventory; COWAT = Controlled Oral Word Association Test – FAS Version; 
CPT II = Connors’ Continuous Performance Test II, CVLT = California Verbal Learning Test, FTT = Finger Tapping Test; FIS = Fatigue Impact Scale, FSS = Fatigue Severity Scale; LNS = Letter Number Sequencing 
from Wechsler Adult Intelligence Scale III, HDRS = Hamilton Rating Scale for Depression; MADRS = Montgomery and Asberg Depression Rating Scale; MFIS = Modified Fatigue Impact Scale; MHI = Mental 
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Health Inventory; MSQOL = Multiple Sclerosis Quality of Life Scale; PASAT = Paced Auditory Serial Addition Test; PDQ = Perceived Deficits Questionnaire; PSDS = Processing Speed Difficulties Scale; RFF = Ruff 
Figural Fluency Test; SDMT = Symbol Digit Modalities Test; SEP - 59 = Self-Administered Health Related Quality of Life Questionnaire; SPART = Spatial Recall Test; SRT = Selective Reminding Test, TOL = 
Tower of London; UKNDS = UK Neurological Disability Scale; WAIS = Wechsler Adult Intelligence Scale; WAIS-R = Wechsler Adult Intelligence Scale – Revised; WLG = Word List Generation, WMS =Wechsler 
Memory Scale 
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Table 2 
Quality review table 
 Delorie,  
Bonnet,  
Salort,  
Arimone,  
Boudineau, Petry 
& Brochet (2006) 
Jones (2012) Kinsinger & 
Lattie (2010) 
Marrie, Chelune, 
Miller & Cohen 
(2005) 
Middleton, 
Denny, Lynch & 
Parmenter (2006) 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 1 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 2 
Explicit theoretical 
framework  
3 3 3 3 3 3 3 
Aims/objectives in main 
body of report  
3 3 3 3 3 3 3 
Clear description of 
research setting 
3 3 2  3 2 2 2 
Evidence of sample size 
considered in terms of 
analysis 
0 3 0 0 0 0 0 
Representative sample of 
target group of reasonable 
size 
2 2 2 2 2 1 2 
Description of procedure 
for data collection 
1 3 3 1 3 1 1 
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 Delorie,  
Bonnet,  
Salort,  
Arimone,  
Boudineau, Petry 
& Brochet (2006) 
Jones (2012) Kinsinger & 
Lattie (2010) 
Marrie, Chelune, 
Miller & Cohen 
(2005) 
Middleton, 
Denny, Lynch & 
Parmenter (2006) 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 1 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 2 
Rationale for choice of 
data collection tools 
2 3 1 2 2 2 2 
Detailed recruitment data 
provided   
1 2 3 2 2 1 1 
Statistical assessment of 
reliability/validity of data 
collection tools 
1 3 3 0 0 1 1 
Fit between stated 
research question and 
method of data collection 
3 3 2 3 3 3 3 
Fit between research 
question and method of 
analysis 
3 3 3 3 3 3 3 
Good justification for 
analytical method selected 
3 3 3 3 1 2 2 
Evidence of user 
involvement in design 
0 0 0 0 0 0 0 
  
7
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 Delorie,  
Bonnet,  
Salort,  
Arimone,  
Boudineau, Petry 
& Brochet (2006) 
Jones (2012) Kinsinger & 
Lattie (2010) 
Marrie, Chelune, 
Miller & Cohen 
(2005) 
Middleton, 
Denny, Lynch & 
Parmenter (2006) 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 1 
Roberg Bruce, 
Lovelace & 
Lynch (2012)  
– Study 2 
Strengths and limitations 
critically discussed 
2 3 2 2 1 2 2 
Total 27 37 30 27 25 24 25 
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Author guidelines: Health Psychology Review 
 
Full guidelines: 
www.tandfonline.com/action/authorSubmission?journalCode=rhpr20&page=instructions#.U
4IkUfldVNM 
 
General guidelines 
 Manuscripts are accepted in English. British English spelling and punctuation are 
preferred. Please use single quotation marks, except where ‘a quotation is “within” 
a quotation’. Long quotations of 40 words or more should be indented without 
quotation marks. 
 The editorial team acknowledge that review articles are usually longer than 
empirical articles. However, it is also recognised that articles should be concise and 
pithy so that the main focus of the article is not lost and the argument is not 
encumbered by unnecessary detail. Articles to Health Psychology Review should 
therefore be no longer than 30 double-spaced manuscript pages in length with 
2.4cm margins (minimum) including abstract, main text, references, footnotes, 
figures and tables. Authors can include additional figures and tables not directly 
germane to the main argument of the manuscript as online supplemental materials. 
For meta-analyses and systematic reviews, references for studies included in the 
review should be only appear in a separate supplemental list that the journal will 
make available as an online supplement. These materials will not count toward the 
page length of the manuscript, but will be included as a permanent record of 
supplemental materials alongside the online version of the manuscript (see later). 
Manuscripts should be compiled in the following order: title page; abstract; 
keywords; main text; acknowledgements; references; appendices (as appropriate); 
table(s) with caption(s) (on individual pages); figure caption(s) (as a list). 
 Abstracts of 200 words are required for all manuscripts submitted. 
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 Each manuscript should have 3 to 6 keywords . 
 Search engine optimization (SEO) is a means of making your article more   visible 
to anyone who might be looking for it. Please consult our guidance. 
 Section headings should be concise. 
 All authors of a manuscript should include their full names, affiliations, postal 
addresses, telephone numbers and email addresses on the cover page of the 
manuscript. One author should be identified as the corresponding author. Please 
give the affiliation where the research was conducted. If any of the named co-
authors moves affiliation during the peer review process, the new affiliation can be 
given as a footnote. Please note that no changes to affiliation can be made after the 
manuscript is accepted. Please note that the email address of the corresponding 
author will normally be displayed in the article PDF (depending on the journal 
style) and the online article. 
 All persons who have a reasonable claim to authorship must be named in the 
manuscript as co-authors; the corresponding author must be authorized by all co-
authors to act as an agent on their behalf in all matters pertaining to publication of 
the manuscript, and the order of names should be agreed by all authors. 
 Biographical notes on contributors are not required for this journal. 
 Please supply all details required by any funding and grant-awarding bodies as an 
Acknowledgement on the title page of the manuscript, in a separate paragraph, as 
follows: 
 For single agency grants: "This work was supported by the [Funding Agency] 
under Grant [number xxxx]." 
 For multiple agency grants: "This work was supported by the [Funding Agency 1] 
under Grant [number xxxx]; [Funding Agency 2] under Grant [number xxxx]; and 
[Funding Agency 3] under Grant [number xxxx]." 
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 Authors must also incorporate a Disclosure Statement which will acknowledge any 
financial interest or benefit they have arising from the direct applications of their 
research. 
 For all manuscripts non-discriminatory language is mandatory. Sexist or racist 
terms must not be used. 
 Authors must adhere to SI units . Units are not italicised. 
 When using a word which is or is asserted to be a proprietary term or trade mark, 
authors must use the symbol ® or TM. 
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My role in the research 
 
This study was a component of a larger study investigating cognitive functioning and 
subjective wellbeing in Neuromyelitis Optica (NMO), Multiple Sclerosis (MS) and healthy 
controls.   The primary aim in the larger study is to investigate the prevalence of cognitive 
impairment in patients with NMO, MS and healthy controls.  The secondary aim, in the 
larger study, is to investigate quality of life, emotion well-being, and self-efficacy.  This 
study already had ethical approval. 
 
The research question for this study was developed from the secondary aim of the larger 
study.  This was developed by me, in conjunction with my supervisors.  Based on the 
research question, an ethical amendment was submitted and approved, permitting the 
recruitment of additional participants.  I personally recruited and assessed 35 participants.  I 
also scored, input and analysed all of the MS data.   
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Power calculation 
 
Faul et al. 
1
 provide guidelines for using G*Power to determine sample size and power.   A 
medium and large effect size was demonstrated for the quality of life and the perceived 
deficits hierarchical regression respectively.  The R² values for the quality of life regression 
(.51 for step 3 and .58 for step 4) were converted to an f² value (0.18).  This f² value was 
entered into G*Power to determine whether there was an adequate sample size.  Based on a 
medium effect size using an  = 0.05, with one tested  predictor variable (self-efficacy) and 
eight total predictor variables (age, MS duration, fatigue, anxiety, depression, composite 
objective cognitive functioning, executive functioning and self-efficacy) and an 80% chance 
of power being detected, 45 participants were required for this study. 
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Neuropsychological tests 
 
Visual Reproduction 
A visual memory test from the Wechsler Memory Scale WMS IV, 
1
 examining immediate, 
delayed recall and delayed recognition.  Test retest reliability has been measured at r=0.93 
for the immediate recall task and r=0.97 for the delayed recall task 
1
. 
 
Symbol Digit Modalities Test SDMT, 
2
 
The SDMT is a measure of information processing speed.  The test can be used with 
participants with motor impairments as it requires verbal responses.  The test-retest 
reliability has been measured at between r = 0.82 and r=0.95 within a MS population 
3
. 
 
California Verbal Learning Test-II 
4
 
A test of verbal learning and memory, and is the most commonly used measure of memory 
within the MS population.  The CVLT-II has been found to have high test-retest reliability 
(r=0.80 to r=0.89) for the immediate recall tasks, and adequate reliability for the long delay 
task (r=0.70 to r=0.79) 
4
. 
 
Hayling 
5
 
A clinical test of executive functioning, specifically measuring response ignition and 
suppression, that is suitable for people with visual and motor impairments.  Test retest 
reliability has been demonstrated between r=0.62 to r=0.78 
5
. 
 
Verbal fluency  
The verbal fluency is a component of the Delis-Kaplan Executive Functioning System 
6
.  A 
test of verbal, category and switching fluency used to assess executive functioning.  Test-
retest reliability, for adults aged 18-89, ranges from r=0.77 to r=0.90, r=0.60 to r=0.76 and 
r=0.51 to r=0.72 for verbal, category and switching fluency respectively 
6
. 
88 
 
 
Digit Span 
The Digit Span task is a subtest that forms part of the Wechsler Adult Intelligence Scale 
fourth Edition WAIS-IV, 
7
. It is a measure of auditory attention and working memory.  The 
measure has been found to have test-retest reliability at r=0.93 
8
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Data screening analysis 
 
Prior to conducting statistical analysis, preliminary analyses were performed to ensure 
parametric assumptions were met.   
 
Multicollinearity 
Tolerance and VIF values were produced to check the assumption of multicollinearity.  
Pallant 
1
 suggests that low tolerance values, under .10, and high VIF values, over 10, 
suggests the possibility of multicollinearity. The tolerance value for each independent 
variable was below .10 and the VIF values were above 10 for both regression analyses.  
 
Outliers, normality, linearity, homoscedasticity and independence of residuals 
P-P plots were produced with data points falling close to the diagonal line, suggesting no 
major deviations from normality.  Scatterplots were also produced and the standardised 
residuals were roughly rectangularly distributed.  The scatterplot was also examined for the 
presence of outliers.  Additionally, the presence of outliers was assessed by examining the 
Mahalanobis distance and Cook’s distance.  Pallant (2013) recommends a Mahalanobis 
value of less than 24.32 with seven predictor variables, and a Cook’s distance of less than 1.  
Manhalanobis and Cook’s distance were in the recommended range for both regression 
analyses.   
 
Missing Data  
Three participants were unable to complete the visual memory drawing task due to motor 
and sensory difficulties in their arm or hand.  A further participant was unable to complete 
the visual memory task, category fluency and verbal fluency due to unexpected time 
constraints.  This represented less than 3% of the total objective cognitive functioning data.   
Schafer 
2
 suggests this is in within the recommended range of fewer than 5%.  There was no 
missing data for any other variables.   
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Author guidelines:  Multiple Sclerosis Journal 
 
Full guidelines: http://www.uk.sagepub.com/msg/msj.htm 
 
Article Type Abstract Main text  References Figures/Tables  
Research paper 200 3000* Up to 35 As necessary 
*excludes references, tables and legends  
 
Original research papers should be no more than 3,000 words and contain the following 
sections: Title page, Abstract, Introduction, Materials (or patients or animals) and Methods, 
Results, Discussion, Acknowledgements, References, Tables, Figure legends, Figures (see 
‘Sections of the manuscript’ for further details). 
 
Journal Style 
Multiple Sclerosis Journal conforms to the SAGE house style.  Click here to review 
guidelines on SAGE UK House Style 
In addition to the details in the above style guide, please note the following: 
Units, symbols and abbreviations 
For detailed advice please refer to the guidelines in Baron, DN (1988). Units, symbols and 
abbreviations, 4th edn. (Obtainable from The Royal Society of Medicine, 1 Wimpole Street, 
London W1M 8AE, UK). Note that the SI system of units is preferred. Because of the 
multidisciplinary nature of the readership and to avoid confusion, the number of 
abbreviations in the text should be kept to a minimum. Standard abbreviations acceptable 
without definition are limited to the following: 
CNS (central nervous system); CSF (cerebrospinal fluid); DNA (deoxyribonucleic acid); 
HLA (human leukocyte antigen; MRI (magnetic resonance imaging); CT (computerized 
tomography); MS (multiple sclerosis); RNA (ribonucleic acid). Nonstandard definitions 
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must be defined in full at their first usage in the abstract and again at their first use in the 
text. 
 
Reference Style 
Multiple Sclerosis Journal adheres to the SAGE Vancouver reference style. Click here to 
review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this 
reference style. 
 
If you use EndNote to manage references, download the SAGE Vancouver output file by 
following this link and save to the appropriate folder (normally for Windows C:\Program 
Files\EndNote\Styles and for Mac OS X Harddrive:Applications:EndNote:Styles). Once 
you’ve done this, open EndNote and choose “Select Another Style...” from the dropdown 
menu in the menu bar; locate and choose this new style from the following screen. 
Alternatively visit the EndNote website and search the Styles section for ‘SAGE 
Vancouver’. 
Manuscript Preparation 
Submitting a new manuscript through the online system: 
When making a submission, the following separate, unpaginated documents should be 
uploaded. Please do not submit one combined document. The separate files will be combined 
into a pdf in the online system. 
1. Title page (title, names of authors, affiliations, keywords, corresponding 
author) 
2. Main document (includes structured abstract, main text, acknowledgements, 
references) 
3. Tables (each as a separate Word document) 
4. Figure legends (Word document) 
5. Figures (as separate tiff, jpg or eps files) 
6. Any supplementary files 
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Title page 
The title should be concise with no abbreviations. Please provide the surname, initials, 
department, institution, city and country of each author, and the name, email address, full 
mailing address, telephone number and fax number of the corresponding author to whom 
proofs should be sent. List six to eight keywords (chosen from Index Medicus, Medical 
Subject Headings if possible). 
Abstract 
The second page of the manuscript must contain only the abstract, which should be of no 
more than 200 words and must be clearly written and comprehensive to readers before they 
have to read the paper.  The abstract should be structured according to the following sub 
headings: Background, Objective, Methods, Results and Conclusion. Abbreviations should 
be avoided and reference citations are not permitted. 
Any manuscripts submitted without a structured abstract will be returned to the 
author immediately without peer review, thus delaying the evaluation process of the 
manuscript.  
 
Introduction 
The introduction should assume that the reader is knowledgeable in the field and be as 
brief as possible. 
Materials and Methods 
Methods that have been published in detail elsewhere should not be described in detail. 
Avoid unnecessary detailed descriptions of widely used techniques. SI Units should be used 
throughout the text. Reports of experiments involving patients and healthy volunteers must 
describe the steps taken to obtain consent and to maintain confidentiality. Experiments 
involving animals must conform to accepted ethical standards. 
Tables 
Tables should be submitted in Word, typed on separate pages. Tables should be numbered 
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consecutively with Arabic numerals, and cited as such in the manuscript. 
The preferred placing of tables in the main text should be indicated. Tables should include a 
brief descriptive title and be self-explanatory. Footnotes to tables indicated by lower-case 
superscript letters are acceptable, but they should not include extensive experimental details. 
 
 
 
 
 
 
 
